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A b s t r a c t
The aim of this paper is to describe the possibilities of the therapeutic use of hyaluronic acid (HA) in the treatment of osteoarthritis 
of  knee  cartilage.  This  work  provides  an  overview  of  the  literature  relating  to  the  structure  of  hyaluronic  acid,  its  properties 
and important functions of the human body. Moreover, the construction of the articular cartilage in the knee joint, including events 
leading  to  its  degeneration,  is  presented. Viscosupplementation  is  a  treatment  for  osteoarthritis  involving  several  intra-articular 
injections  of HA  at  specific  time  intervals. This  treatment  results  in  an  increased  lubricity,  viscosity  and  elasticity  of  articular 
cartilage.  Since  HA  is  found  naturally  in  the  human  body,  viscosupplementation  improves  the  biomechanical  conditions  
of  the  joint  whilst  minimizing  the  side-effects  of  treatment.  Hyaluronic  acid  occurs  naturally  in  a  linear  form,  but  for  many 
applications,  chemical  modifications  are  necessary.  Thanks  to  this  property,  it  remains  in  the  body  long  enough  to  produce 
the desired  therapeutic effect. Modification processes,  in particular  the cross-linking of HA,  increase  the mechanical properties 
of knee cartilage. HA is an example of a new kind of tissue engineering scaffold that is bioactive in both full-length and degraded 
forms.  In  turn, hydrogel  scaffolds with  interpenetrating polymeric network  (IPN) gels  can  simulate  the  structure of    the native 
extracellular matrix of cartilage tissue.
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S t r e s z c z e n i e
Celem badań  jest przedstawienie możliwości  terapeutycznego zastosowania kwasu hialuronowego w  leczeniu choroby zwyrod-
nieniowej  chrząstki  stawu kolanowego. Praca  zawiera  przegląd  literatury dotyczący  struktury  kwasu hialuronowego,  jego wła-
ściwości oraz ważnych funkcji jakie pełni w ludzkim organizmie, ponadto budowy chrząstki stawowej w stawie kolanowym oraz 
czynników prowadzących do jej degeneracji. Wiskosuplementacja jest metodą leczenia osteoporozy polegającą na dostawowych 
wstrzyknięciach tego biopolimeru w określonych odstępach czasu oraz kilkakrotnych powtórzeniach. Leczenie zwiększa lepkość 
oraz elastyczność chrząstki stawowej, która jest lepiej odżywiana. Wiskosuplementacja poprawia warunki biomechaniczne stawu, 
co więcej kwas hialuronowy występuje naturalnie w organizmie człowieka, w ten sposób pomaga zminimalizować skutki uboczne 
leczenia. W naturalnej postaci kwas hialuronowy występuje w postaci liniowej, ale w wielu zastosowaniach konieczna jest jego 
modyfikacja chemiczna. Dzięki tej właściwości pozostaje w organizmie na tyle długo, aby wywołać pożądany efekt terapeutyczny. 
Procesy modyfikacji, w szczególności sieciowanie kwasu hialuronowego zwiększa właściwości mechaniczne materiału. Badania 
potwierdzają, że hydrożelowe rusztowania z wzajemnie przenikającymi się sieciami polimerowymi (IPNs) mogą symulować struk-
turę natywną macierzy zewnątrzkomórkowej chrząstki.
Słowa kluczowe: kwas hialuronowy, chrząstka kolanowa, osteoporoza, wiskosuplementacja, IPNs, rusztowania
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1. Introduction
Hyaluronic acid (HA) is a polysaccharide composed of repeating disaccharide units 
containing D-glucuronic acid and N-acetyl-D-glucosamine alternating b-(1-4) and b-(1-3) 
glycosidic bonds (Fig. 1).
HA is a biopolymer which is present in all living organisms and is the largest group 
of compounds that has the same chemical structure in bacteria and in humans. In animal 
organisms, hyaluronic acid is synthesized by the cell membrane with hyaluronates synthase, 
which is involved in connecting alternating glucuronic acid and N-acetylglucosamine 
molecules. Hyaluronic synthase has a high level of activity, which allows the synthesis 
of 100 monosaccharide molecules per second under in vitro conditions. There are three 
different types of hyaluronic synthase: Has 1, Has 2 and Has 3. Has 3 is the most active, 
able to polymerize large amounts of HA of up to 2×105 Da. Hyaluronic acid is present in 
human skin, cartilage, synovial fluid, the corpus vitreous of the eye, the kidneys, the brain, 
umbilical cord tissue, urine and serum [1]. Table 1 shows the amount of HA in various parts 
of the human body.
T a b l e  1
Quantities of hyaluronic acid in human body parts
Locus in the human body Hyaluronic acid content
an adult weighing 70 kg 15 g HA
dermis 200–500 ug/ml HA
human umbilical cord 4100 ug/ml
synovial fluid of the joint capsule 1400–3600 ug/ml
corpus vitreous of the eye 190- 320 ug/ml
epidermis 100 ug/ml
The amount of hyaluronic acid in the body is dependent upon age – the greatest 
concentration is in the skin of infants and children, and the smallest, for people over 
50 years of age (Fig. 2). The concentration of HA is also dependent on the season – UV 
Fig. 1. Structure of hyaluronic acid
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photodegradation is the process leading to photoaging of the skin in the summer, of which 
the physical symptoms are dry skin and wrinkles. An important property of HA is its high 
water binding capacity and retention. A single HA molecule is able to bind 200–500 water 
molecules. Another very important feature of HA is its ‘biocompatibility’, which means that 
it does not cause adverse reactions in the body because it naturally occurs in the skin and can 
be completely absorbed by the body [2]. Figure 2 shows the level of HA in connective tissue.
HA plays an important role in connective tissue, it acts as a matrix. HA helps to keep 
the skin hydrated and flexibile and protects the retina. HA also affects homeostasis, together 
with vasopressin, it regulates the reabsorption of water into the spinal cord. An important 
function of HA is to maintain the connection between the mother and the fetus, the facilitation 
of the oocyte release during ovulation, the increasing of sperm motility and fertilization 
efficiency. HA affects a number of processes including the induced expression of cytokines, 
the stimulation of immune and angiogenic processes. A very important function of HA is its 
participation in chondrogenesis and providing adequate lubrication of joints which reduces 
the friction between the moving bones, thereby decreasing the process of osteoarthritis [3].
Articular cartilage is a complex tissue that covers the surfaces in contact with each 
bone, prevents abrasion and facilitates slippage. Its role is to provide free and accurate 
movement in the joint [4].
Articular cartilage tissue is alive, resilient, resistant to mechanical stress and has little 
regenerative capacity. This cartilage is composed of chondrocytes i.e. only cells found in 
cartilage that produce and maintain the cartilaginous matrix by producing collagen and 
proteoglycans. In articular cartilage, four basic layers can be distinguished, each with varying 
amounts of collagen and water (Fig. 3). Zone 1 is called the surface layer and displays the most 
stiffness. Zone 2 is an intermediate zone, where cells are randomly distributed and have a more 
spherical shape. Chondrocytes arranged in columns perpendicular to the articular surface 
are grouped on Zone 3. Zone 4 is the deepest, calcified, and is adjacent to the subchondral 
bone. Synovial fluid nourishes the articular cartilage. The necessary condition for the proper 
nutrition of cartilage is the movement and loading of articular surface. Chondrocytes are 
supplied with oxygen and nutrients from the synovial fluid by diffusion.
Fig. 2. The level of hyaluronic acid in connective tissue
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Water makes up about 75% of cartilage – the highest concentration of water is in the 
deeper layers of the cartilage. The pressure of hydrostatic compression of cartilage causes 
the extrusion of a small amount of water which forms a layer and reduces friction in the joint.
Other components of the articular cartilage that provides durability and low friction 
are collagen protein (60% dry weight) and proteoglycan aggregates (30% dry weight). 
Chondrocytes are sensitive to mechanical stimuli, growth factors, cytokines and receptors. 
Chondrocytes secrete both the matrix components and the enzymes degrading it. They are 
responsible for the homeostasis of the cell. Cartilage proteoglycans consist of a protein core 
to which are attached glycosaminoglycans. This cartilage proteoglycan chondroitin sulfate A, 
C, and keratan sulfate are important aggrecans capable of binding to HA [5]. Figure 4 shows 
the appearance of a healthy knee joint in comparison to a degenerate knee joint.
Knowledge of the structure and physiology of cartilage allows for understanding the 
pathomechanisms responsible for the destruction in the course of injury, degenerative 
Fig. 3. Articular cartilage matrix
Fig. 4. Healthy knee joint in comparison to degenerate knee joint
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diseases and autoimmune diseases. Degeneration of articular cartilage is a growing problem 
of civilization. Until recently, the disease was characteristic of old age. Nowadays, more 
young patients receive medical consultation due to joint pain. The causes of degenerative 
changes can be: multiple injuries (sports, work); microfractures; chronic stress caused 
by impaired limb axis; instability or damage to the meniscus; ligamentous instability; 
rheumatism; obesity [6]. These processes destroy the joints. The disease causes the abnormal 
changes in synovial fluid, the increased friction of the articular surfaces or the destruction 
of cartilage. Due to the depth and nature of the damage, articular cartilage is the third 
most common disease in Central and Eastern Europe (after the ischemic heart disease and 
vascular diseases of the brain). It usually occurs in the range of 45 to 59 years of age (WHO, 
1989), and the other in Western Europe (after the ischemic heart). The prevalence of this 
condition in the population by age is as follows: under 25 years of age – 4%; under 35 years 
of age – 5%; over 65 years of age – 70%; in the range 75–79 years – 85%. In Poland, it is 
estimated that about 8 million people have damage to articular cartilage – 40 % relates to hip 
and 25% is degeneration of knee joints [8, 9]
Prevention of degradative changes of articular cartilage is possible in early stage. Articular 
cartilage and synovial fluid cushion the joint. Properties of HA act on smooth movements 
in all joints, increasing the viscosity of the synovial fluid. Due to the presence of HA, joints 
are better hydrated, nourished and avoid the release of free radicals.
Research shows that human synoviocytes derived from degenerative arthritis which 
were incubated with the exogenous HA, synthesize larger amounts of HA and of a higher 
molecular weight [10].
2. Intra-articular injections of HA
The human body contains approximately 15 grams of pure HA produced by synovial 
cells. Its defects are increasingly replaced by a synthetic counterpart, introduced by intra- 
-articular injection. Viscosupplementation is a method which consists of intra-articular HA 
supplementation administered every seven days, and repeated three to five times [11]. This is 
a common treatment which has been used for over 20 years for osteoarthritis [12–17]. Many 
studies confirm the effectiveness of viscosupplementation [18–37]. This treatment increases 
the viscosity and flexibility of synovial fluid [38]. For clinical use, a number of derivatives 
of HA are available. They are characterized by different molecular weights and viscosities 
depending upon their source (e.g. rooster combs or hyaluronans secreted by streptococci). 
Sodium hyaluronan (Hyalgan, Sanofi Synthelabo Inc., New York, NY), and hylan GF-20 
(Synvisc, Wyeth-Ayerst Pharmaceuticals, Philadelphia, PA) are available in the United 
States [29]. Positive effects were observed within 7–14 months of three intra-articular Hylan 
GF-20 injections using one hundred and fifty-five patients (male and female) with knee 
osteoarthritis [39]. Hyalgan is a viscous solution of the sodium salt of HA with a molecular 
weight of between 500.000 and 730.000 Da, it is a highly purified fraction of natural sodium 
hyaluronate. Synvisc is chemically cross-linked with formaldehyde and vinyl sulfone; its 
average molecular weight is 6.000.000 Da. Hyalgan has been most commonly administered 
in a cycle comprising five injections over a 4-week period. More recently, approval has been 
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given by the Food and Drug Administration (FDA) for a three-injection series. Synvisc is 
used in a course of one injection weekly for a total of three weeks.
Fig. 5 shows the effect of the Ortovisc preparation for knee pain during 27 weeks 
of therapy the treatment of osteoarthritis [40].
The effect of HA on the course of osteoarthritis was identified after clinical trials on 
patient suffering from this disease. One group of patients was injected with intra-molecular 
weight hyaluronic acid and the other group receiving a placebo [41, 42]
The study was conducted on 301 patients, who received  HA and  placebo. Of patients 
aged over 45 years, 84% were women. The treatment lasted 40 months and involved four 
cycles of five injections of 2,5 ml 1% solution of HA with a molecular weight of 900 kDa 
into the knee joint.
Fig. 5. Orthovisc treatment preparation
Fig. 6. 40 months of therapy with HA and placebo (Osteoarthritis Research 
Society International, 2004)
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According to the criteria OARSI 2004 – 22% higher response in patients treated with HA 
(Fig. 6). In general, the clinical results showed that viscosupplementation with hyaluronic 
acid is most effective in patients aged over 65 years [44–51].
3. Chemical modification of hyaluronic acid
HA is subjected to a process of linear and crosslinking modifications by forming covalent 
bonds between molecules of HA. Modified HA is less susceptible to chemical and enzymatic 
degradation, which allows it to remain in the body long enough to produce the desired 
therapeutic effect [52]. Modification processes, in particular the cross-linking of HA, also 
enhance the mechanical properties of the material. Chemical modifications typically involve 
hydroxyl and carboxyl groups of the polymer.
Alkylation of the ammonium salt of hyaluronic acid with an alkyl halide in a solution 
of DMF leads to the formation of esterified HA biomaterials. Esterification reactions 
involve carboxylate moieties of the polymer. The degree of esterification affects the size 
of the hydrophobic patches and forms a stable, rigid chain network polymer more resistant 
to enzymatic degradation under physiological conditions. Esters of HA are the most utilized 
derivatized HA products.
These products are applied to the growth of chondrocytes and bone marrow derived 
mesenchymal cells for the repair of cartilage and bone defects.
Crosslinking HA is necessary to obtain implantable hydrogel with controlled degradability 
and mechanical properties. Crosslinking hydrogels is the most common modification 
of HA [52]. Crosslinking (binding a polymer with other polymers) of the hyaluronic acid 
results in its stability and extends the natural degradation [53]. Degradation of crosslinked 
HA in the body lasts for several months, whereas the degradation of non-crosslinked HA 
takes a few hours. Viscosity of the crosslinked HA increases and depends on the degree 
of cross-linking between the chains of HA. Thanks to this property remain in the body 
long enough to produce the desired therapeutic effect.
Fig. 7. Basic synthesis methods for IPNs.
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An interpenetrating polymer network, IPN, is defined as a blend of two or more 
polymers in a network form. Figure 7 shows the synthesis method of IPNs.
Hydrogels of collagen/chondroitin sulfate/hyaluronan interpenetrating polymer network 
were used for cartilage tissue engineering [54].
The task of tissue engineering is the development of substitutes for damaged tissue by 
creating three-dimensional scaffolds with living cells and bioactive molecules, which allow 
the proliferation and differentiation of cells. These structures can be created by seeding cells 
within the scaffold or by the injection of cells into the damaged tissue. Injectable scaffolds have 
been used to repair articular cartilage. Injectable biocompatible and biodegradable scaffolds 
derived from chitosan and oxidized hyaluronic acid [55] and injectable hydrogel made 
from methacrylated glycol chitosan (MeGC) and photocrosslinking HA with a ryboflavin 
photoinitiator under visible light were found to be very good options for cartilage repair [56].
Lisognoli investigated human mesenchymal stromal (MSCs) cells in a hyaluronian-based 
polymer scaffold (Hyaff ®-11) by electron microscopy techniques, immunohistochemistry 
and real time PCR. There was a significant proliferation of cells TGFβTGFβ MSCs and 
increased expression of collagen type II, IX within 21 days.
Hyaff-11 was also used as scaffolding for cartilage defects [57–61]. Autocrosslinked 
polysaccharide (ACP) polymers are inter and intra-molecular esters of hyaluronan (HA) 
where part of the carboxyl group is esterified with hydroxyl groups of the same or different 
molecules of polysaccharides. The autocross-linked polymer (ACPTM, Fidia) is used 
as a scaffold for the repair of tissue defects. This biomaterial has been used as a scaffold 
and showed faster regeneration of tissue defects than Hyaff 11 [62].
Scaffold based on HA is a kind of bioactive tissue engineering with a specific interaction 
between the scaffold and growing cells by cell receptors (CD44, RHAMM, ICAM-1) for 
the growth and repair of tissues. Chung IPNs made  with sodium hyaluronic acid/sodium 
alginate (HA/SA) scaffold, where HA and SA were cross-linked with diglycidyl ether 
of polyethylene glycol (PEGDG) and calcium chloride. The study used rabbit chondrocytes 
which are seeded in a HA/SA scaffold. Researchers noticed an increase in the quantity 
of DNA in chondrocytes after 21 days which confirmed their proliferation and increased 
the quantity of collagen type II. These studies demonstrated that porous HA/SA scaffolds 
Fig. 8. SEM image of fabricated HA70/SA30.
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may be used for three-dimensional culture of chondrocytes. A low pore size HA/SA 
(70/30) scaffold about 200 mm is preferable for durability and chondrocyte differentiation 
(Fig. 8) [63].
Hydrogels made from the crosslinked polymers with a high water content can provide 
local delivery of therapeutic agents, because of this benefits are called “intelligent materials”.
4. Conclusions
Intra-articular injections of HA provides hope for improvements in the treatment 
of patients suffering from arthritis, where the concentration of hyaluronic acid conditioning 
the viscoelastic properties of synovial fluid and proper movement in the joint is reduced. 
Viscosupplementation is a treatment for osteoarthritis involving the intra-articular 
injection of HA in appropriate quantities and time intervals. The number publications 
presented in this work confirms of analgesic, anti-inflammatory and articular tissue protect 
functions of HA. Viscosupplementation is an alternative method for treating arthritis. 
Injectable, biodegradable scaffolds based on HA in the form of hydrogels are important 
biomaterials for tissue engineering and drug delivery. Hydrogels derived from HA are 
ideal scaffolds as they resemble the extracellular matrices of tissues comprised of various 
glycosaminoglycans (GAGs).
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